Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Carcinoma, Non-Small-Cell Lung 451Melanoma 287Squamous Cell Carcinoma of Head and Neck 229Parkinson Disease 4, Autosomal Dominant Lewy Body 188Neoplasms 180Triple Negative Breast Neoplasms 162Breast Neoplasms 161Neoplasm Metastasis 156Lung Neoplasms 141Colorectal Neoplasms 140Carcinoma, Renal Cell 129Head and Neck Neoplasms 120Stomach Neoplasms 103Ovarian Neoplasms 101Carcinoma, Transitional Cell 92Urinary Bladder Neoplasms 80Pancreatic Neoplasms 80Endometrial Neoplasms 74Carcinoma, Hepatocellular 72Uterine Cervical Neoplasms 63Esophageal Neoplasms 57Recurrence 52Prostatic Neoplasms 48Sarcoma 43Carcinoma 42Small Cell Lung Carcinoma 39Glioblastoma 39Carcinoma, Squamous Cell 39Hodgkin Disease 36Lymphoma 34

Interventions

Paclitaxel 3Carboplatin 3fludarabine 2aldesleukin 2Radiotherapy, Intensity-Modulated 2Cyclophosphamide 2Cisplatin 2pembrolizumab 1fluoroazomycin arabinoside 1fludarabine phosphate 1figitumumab 1cabozantinib 1Panitumumab 1Nivolumab 1Metformin 1Interleukin-2 1Hysterectomy 1Fluorouracil 1Docetaxel 1Chemoradiotherapy 1Cetuximab 1Albumin-Bound Paclitaxel 111-(2-methylpropyl)-12,13-dihydro-2-methyl-8-(pyrimidin-2-ylamino)-4H-indazolo(5,4-a)pyrrolo(3,4-c)carbazol-4-one 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Carcinoma, Adenosquamous × pembrolizumab × Clear all
NCT04230954 2022-06-07

Cabozantinib Plus Pembrolizumab for Recurrent, Persistent and/or Metastatic Cervical Cancer

University of South Alabama

Phase 2 Terminated
5 enrolled
Gynecologic

Adenocarcinoma, Carcinoma, Squamous Cell, Uterine Cervical Neoplasms, Carcinoma, Adenosquamous

Data powered by HemOnc (CC BY 4.0) Colophon âš¡